MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.71702

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study.

Wu Hao, Chen Qin, Fang Min, Tang Huidong, Liu Huayan, Liu Jun, Zhang Jiewen, Chi Lijun, Liu Shuai, Xin Jiawei, Leng Lumin, Wang Pan, Chi Song, Li Yi, Chen Jianwen, Zhang Ligong, Zhang Jinhong, Ma Qiang, Wang Xuezhen, Meng Xinling, Nao Jianfei, Li Xiangqing, Lv Yan, Jia Yanhong, Zhao Qing, Liu Chunyan, Gan Jinghuan, Zhu Jing, Song Yehua, Li Huaian, Fei Min, Guo Xia, Liu Jingwen, Peng Guoping, Chen Xiaochun, Ji Yong

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

We evaluated lecanemab's safety and cognitive outcomes in Chinese patients with Alzheimer's disease (AD) and the utility of blood-based biomarkers (BBMs) for treatment guidance.

METHODS

A multicenter, real-world cohort enrolled 1042 patients receiving lecanemab, with 453, 359, 97 patients followed up at 3, 6, 12 months, respectively. Safety outcomes included amyloid-related imaging abnormalities (ARIA) and infusion-related reactions (IRRs), and the main clinical outcome was Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) score change.

RESULTS

Of 1,042 patients, ARIA occurred in 7.87%, and IRRs in 16.12%. Discontinuation was 16.51%, mainly due to financial burden. CDR-SB did not change at 12 months overall or in any subgroup. High-accuracy BBMs were the sole AD biomarker assay in 5.28%, with comparable outcomes.

DISCUSSION: Lecanemab exhibited favorable 12-month safety, with no clear evidence of cognitive decline, and BBMs hold potential for treatment guidance. Further studies using a control group are now warranted.

Для цитирования: Wu Hao, Chen Qin, Fang Min, Tang Huidong, Liu Huayan, Liu Jun, Zhang Jiewen, Chi Lijun, Liu Shuai, Xin Jiawei, Leng Lumin, Wang Pan, Chi Song, Li Yi, Chen Jianwen, Zhang Ligong, Zhang Jinhong, Ma Qiang, Wang Xuezhen, Meng Xinling, Nao Jianfei, Li Xiangqing, Lv Yan, Jia Yanhong, Zhao Qing, Liu Chunyan, Gan Jinghuan, Zhu Jing, Song Yehua, Li Huaian, Fei Min, Guo Xia, Liu Jingwen, Peng Guoping, Chen Xiaochun, Ji Yong. Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. DOI: 10.1002/alz.71702.

Предметные рубрики MeSH

AgedAged, 80 and overFemaleHumansMaleAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersChinaTreatment OutcomeAntibodies, Monoclonal, Humanized
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.